Acadia Healthcare's third quarter 2026 revenue and earnings beat expectations as 2026 guidance was raised

Acadia Healthcare reported third quarter 2026 results that exceeded analyst estimates on both the top and bottom lines. The performance was characterized by strong volume growth in the Acute segment and effective capacity expansion, leading management to raise the full-year 2026 guidance ranges for revenue, Adjusted EBITDA, and Adjusted EPS.

Key Highlights

• Same-facility admissions grew 6.6% year-over-year, while same-facility revenue increased 5.2%.
• Acute segment revenue jumped 11.3% to $524.8 million, supported by a 7.5% increase in inpatient volumes.
• Management raised FY 2026 Adjusted EBITDA guidance to a range of $615–$625 million, up from the prior $590–$615 million.
• The company added 220 licensed beds during the quarter, including a 144-bed de novo facility in Florida.